<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00739154</url>
  </required_header>
  <id_info>
    <org_study_id>005062</org_study_id>
    <secondary_id>non</secondary_id>
    <nct_id>NCT00739154</nct_id>
  </id_info>
  <brief_title>Protective Effect of Phenytoin on Glaucoma</brief_title>
  <official_title>Clinical Cohort Study of Association Between Steady State Phenytoin Treatment and Better Clinical Parameters of Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      since glaucoma is considered an optic neuropathy, new treatments for glaucoma are being
      continuously investigated, including neuroprotection.

      Previous studies implied that phenytoin, a potent anti-convulsive drug, has a neuroprotective
      role, and Na+ channels blockage was suggested as a possible mechanism.

      This study predicts that glaucoma patients taking Phenytoin will have a less advanced
      glaucoma as compared to patients not taking the drug. Glaucoma severity will be determined by
      visual acuity, visual fields, optic disc cupping and nerve fiber layer thickness
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will examine adult patients who suffer from glaucoma and epileptic disorders on the
      same time. the study group will include glaucoma patients, being treated with oral Phenytoin
      for their epileptic disorder. The study group will be compared to 2 control groups:

        -  Glaucoma patients with epileptic disorder,receiving different medication than Phenytoin

        -  Glaucoma patients with no epileptic disorder.

           4 parameters will be evaluated for all groups:

             1. Best corrected visual acuity

             2. Optic disc cupping

             3. visual fields and general perimetric indices

             4. peripapillary retinal nerve fiber layer.

      Every participant in the study,after giving his informed consent, will be evaluated by a
      senior ophthalmologist in a single office appointment. The appointment will include a visual
      acuity, complete ophthalmic examination,Humphrey perimetric visual field testing and
      peripapillary RNFL thickness measurement by OCT.

      no drug or other treatment will be given to the participants

      after data collection, average +/-Standard deviation for the 4 parameters will be compared
      between the 3 groups. Student T-test and one- way ANOVA will be used for statistical
      analysis.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">November 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>peripapillary RNFL thickness</measure>
    <time_frame>immediate</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>corrected pattern standard deviation in perimetric visual field</measure>
    <time_frame>immediate</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <condition>Secondary Open Angle Glaucoma</condition>
  <condition>Narrow-Angle Glaucomas</condition>
  <condition>Normal Tension Glaucoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>glaucoma patients who also suffer from epileptic disorder and receiving chronic oral Phenytoin treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>glaucoma patients who also suffer from epileptic disorder receiving anti-convulsant treatment other then Phenytoin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>glaucoma patients with no epileptic disorder and not receiving anti-convulsant treatment</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients of a tertiary hospital's specialized epilepsy clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of glaucoma

          -  chronic treatment with phenytoin for any indication

        Exclusion Criteria:

          -  pregnancy

          -  visual acuity less then 6/60
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omer Y Bialer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Rabin medical center, Petah Tikva, Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dan Gaa'ton, MD</last_name>
    <role>Study Director</role>
    <affiliation>Rabin medical center, Petah-Tikva, Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Omer Y Bialer, MD</last_name>
    <phone>972-39376100</phone>
    <email>omerb2@vlalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dov Weinberger, MD</last_name>
    <phone>972-39376101</phone>
    <email>dwin@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beilinson hospital, Rabin medical center</name>
      <address>
        <city>Petah-Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Chidlow G, Wood JP, Casson RJ. Pharmacological neuroprotection for glaucoma. Drugs. 2007;67(5):725-59. Review.</citation>
    <PMID>17385943</PMID>
  </reference>
  <reference>
    <citation>Ben Simon GJ, Bakalash S, Aloni E, Rosner M. A rat model for acute rise in intraocular pressure: immune modulation as a therapeutic strategy. Am J Ophthalmol. 2006 Jun;141(6):1105-11.</citation>
    <PMID>16765680</PMID>
  </reference>
  <reference>
    <citation>Willmore LJ. Antiepileptic drugs and neuroprotection: current status and future roles. Epilepsy Behav. 2005 Dec;7 Suppl 3:S25-8. Epub 2005 Oct 18. Review.</citation>
    <PMID>16239127</PMID>
  </reference>
  <reference>
    <citation>Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG, Chang W, Hee MR, Flotte T, Gregory K, Puliafito CA, et al. Optical coherence tomography. Science. 1991 Nov 22;254(5035):1178-81.</citation>
    <PMID>1957169</PMID>
  </reference>
  <reference>
    <citation>Mills RP, Budenz DL, Lee PP, Noecker RJ, Walt JG, Siegartel LR, Evans SJ, Doyle JJ. Categorizing the stage of glaucoma from pre-diagnosis to end-stage disease. Am J Ophthalmol. 2006 Jan;141(1):24-30.</citation>
    <PMID>16386972</PMID>
  </reference>
  <results_reference>
    <citation>Klein BE, Klein R, Sponsel WE, Franke T, Cantor LB, Martone J, Menage MJ. Prevalence of glaucoma. The Beaver Dam Eye Study. Ophthalmology. 1992 Oct;99(10):1499-504.</citation>
    <PMID>1454314</PMID>
  </results_reference>
  <results_reference>
    <citation>Ates O, Cayli SR, Gurses I, Turkoz Y, Tarim O, Cakir CO, Kocak A. Comparative neuroprotective effect of sodium channel blockers after experimental spinal cord injury. J Clin Neurosci. 2007 Jul;14(7):658-65.</citation>
    <PMID>17532502</PMID>
  </results_reference>
  <results_reference>
    <citation>Podos SM, Becker B, Beaty C, Cooper DG. Diphenylhydantoin and cortisol metabolism in glaucoma. Am J Ophthalmol. 1972 Sep;74(3):498-500.</citation>
    <PMID>5053695</PMID>
  </results_reference>
  <results_reference>
    <citation>Naskar R, Quinto K, Romann I, Schuettauf F, Zurakowski D. Phenytoin blocks retinal ganglion cell death after partial optic nerve crush. Exp Eye Res. 2002 Jun;74(6):747-52.</citation>
    <PMID>12126947</PMID>
  </results_reference>
  <results_reference>
    <citation>Lo AC, Black JA, Waxman SG. Neuroprotection of axons with phenytoin in experimental allergic encephalomyelitis. Neuroreport. 2002 Oct 28;13(15):1909-12.</citation>
    <PMID>12395089</PMID>
  </results_reference>
  <results_reference>
    <citation>Hains BC, Waxman SG. Neuroprotection by sodium channel blockade with phenytoin in an experimental model of glaucoma. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4164-9.</citation>
    <PMID>16249495</PMID>
  </results_reference>
  <results_reference>
    <citation>Savini G, Bellusci C, Carbonelli M, Zanini M, Carelli V, Sadun AA, Barboni P. Detection and quantification of retinal nerve fiber layer thickness in optic disc edema using stratus OCT. Arch Ophthalmol. 2006 Aug;124(8):1111-7.</citation>
    <PMID>16908813</PMID>
  </results_reference>
  <results_reference>
    <citation>Carpineto P, Ciancaglini M, Zuppardi E, Falconio G, Doronzo E, Mastropasqua L. Reliability of nerve fiber layer thickness measurements using optical coherence tomography in normal and glaucomatous eyes. Ophthalmology. 2003 Jan;110(1):190-5.</citation>
    <PMID>12511365</PMID>
  </results_reference>
  <results_reference>
    <citation>Williams ZY, Schuman JS, Gamell L, Nemi A, Hertzmark E, Fujimoto JG, Mattox C, Simpson J, Wollstein G. Optical coherence tomography measurement of nerve fiber layer thickness and the likelihood of a visual field defect. Am J Ophthalmol. 2002 Oct;134(4):538-46.</citation>
    <PMID>12383810</PMID>
  </results_reference>
  <results_reference>
    <citation>Budenz DL, Chang RT, Huang X, Knighton RW, Tielsch JM. Reproducibility of retinal nerve fiber thickness measurements using the stratus OCT in normal and glaucomatous eyes. Invest Ophthalmol Vis Sci. 2005 Jul;46(7):2440-3.</citation>
    <PMID>15980233</PMID>
  </results_reference>
  <results_reference>
    <citation>Leung CK, Chan WM, Chong KK, Yung WH, Tang KT, Woo J, Chan WM, Tse KK. Comparative study of retinal nerve fiber layer measurement by StratusOCT and GDx VCC, I: correlation analysis in glaucoma. Invest Ophthalmol Vis Sci. 2005 Sep;46(9):3214-20.</citation>
    <PMID>16123421</PMID>
  </results_reference>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2008</study_first_submitted>
  <study_first_submitted_qc>August 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2008</study_first_posted>
  <last_update_submitted>August 20, 2008</last_update_submitted>
  <last_update_submitted_qc>August 20, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2008</last_update_posted>
  <responsible_party>
    <name_title>prof. Dov Weinberger, head of ophthalmology department</name_title>
    <organization>Rabin medical center</organization>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <keyword>Phenytoin</keyword>
  <keyword>retinal nerve fiber layer</keyword>
  <keyword>corrected pattern standard deviation</keyword>
  <keyword>visual acuity</keyword>
  <keyword>optic disc cupping</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Low Tension Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Angle-Closure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenytoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

